SCHEMBL666569

SCHEMBL666569

NCCCCCCCCCC[C]=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 8/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA3 P07451 2/20 0.50
CA4 P22748 2/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
TSHR P16473 2/20 0.50
LMNA P02545 2/20 0.50
BLM P54132 1/20 0.50
NFKB1 P19838 1/20 0.44
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959776 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL8811124 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL1960836 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL8812186 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL666946 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL381495 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL186389 1.00
SCHEMBL98073 1.00
SCHEMBL8812602 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3
SCHEMBL465588 1.00 DNM1 (0.50) DNM1CA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112851755-A Linear lipopeptide compound and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2021-05-28 CN claimed
US-9621077-B2 Method for manufacturing energy harvester comprising piezoelectric polymer microstructure array XI'AN JIAOTONG UNVERSTIY (CN) 2017-04-11 US claimed
CN-105811805-A Miniature generator based on train bogie railway vibrational energy collection 西南交通大学 2016-07-27 CN claimed
US-20150236620-A1 METHOD FOR MANUFACTURING ENERGY HARVESTER COMPRISING PIEZOELECTRIC POLYMER MICROSTRUCTURE ARRAY XI'AN JIAOTONG UNIVERSITY (CN) 2015-08-20 US claimed
EP-1594835-A4 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS INC (US) 2007-05-02 EP claimed
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses HONG BORCHERNG 2006-08-03 US claimed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP claimed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO claimed
EP-0673254-A4 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. ABBOTT LAB (US) 1998-11-18 EP claimed
JP-H09501913-A 1997-02-25 JP claimed
EP-0738154-A1 N-TERMINUS MODIFIED ANALOGS OF LHRH Abbott Laboratories (US) 1996-10-23 EP claimed
JP-H08504209-A 1996-05-07 JP claimed
EP-0738154-A4 N-TERMINUS MODIFIED ANALOGS OF LHRH ABBOTT LAB (US) 1996-04-12 EP claimed
US-5502035-A N-terminus modified analogs of LHRH TAP HOLDINGS INC. (US) 1996-03-26 US claimed
EP-0673254-A1 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1995-09-27 EP claimed
WO-1995004540-A1 N-TERMINUS MODIFIED ANALOGS OF LHRH ABBOTT LABORATORIES (US) 1995-02-16 WO claimed
WO-1995004541-A1 N-TERMINUS MODIFIED ANALOGS OF LHRH ABBOTT LABORATORIES (US) 1995-02-16 WO claimed
WO-1994013313-A1 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1994-06-23 WO claimed
US-11458212-B2 Molecular imaging of cancer cells in vivo H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-10-04 US disclosed
EP-0337334-A2 Renin-inhibiting amino acid derivatives MERCK PATENT GmbH (DE) 1989-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11458212-B2 Molecular imaging of cancer cells in vivo MKI67, ANXA4, ANXA3 DNM1 363/4885CA12 141/4885CA1 629/4885
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses LSS, DHPS, CYP51A1 DNM1 2292/4885CA12 4278/4885CA1 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.